OpenAI Launches GPT-Rosalind for Drug Discovery

OpenAI launched GPT-Rosalind on April 17, 2026, as a specialized AI tool for life sciences research ^[1]. The model focuses on biochemistry, genomics, and protein engineering to assist scientific teams ^[2]. It helps with synthesizing evidence and generating new hypotheses for complex drug discovery ^[3]. This new tool aims to speed up the early stages of medical research and development ^[2]. It also assists researchers in designing experiments more effectively through advanced reasoning ^[3]. By entering this specialized field, OpenAI is competing directly with similar AI projects from Google ^[1].